evicamtide
Phase 3Peptide
Bayerevicamtide is one of 35 therapeutic programs targeting IgA Nephropathy. It is currently in Phase 3.
1
Indications
0
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
99 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LNP023
NovartisPhase 3
Medrol
PfizerPhase 2
Vanrafia
NovartisPhase 2
Telitacicept
VVor Biopharma
Phase 3
Mezagitamab
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for evicamtide. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- Peptide
- Highest Phase
- Phase 3
- Company